Silver Book Fact

For beneficiaries with wet age-related macular degeneration (AMD), annual Medicare part B payments for vision care increased from $1,504 per beneficiary in 1994 to $3,263 in 2006–due in large part to anti-VEGF treatments.

Day, Shelley, Kofi Acquah, Paul P. Lee, Prithvi Mruthyunjaya, and Frank A. Sloan. Medicare Costs for Neovascular Age-Related Macular Degeneration, 1994-2007. Ophthalmol. May 2011; 152(6): 1014-20. http://www.ajo.com/article/S0002-9394%2811%2900410-7/abstract

Reference

Title
Medicare Costs for Neovascular Age-Related Macular Degeneration, 1994-2007
Publication
Ophthalmol
Publication Date
May 2011
Authors
Day, Shelley, Kofi Acquah, Paul P. Lee, Prithvi Mruthyunjaya, and Frank A. Sloan
Volume & Issue
Volume 152, Issue 6
Pages
1014-20
URL
Read Full Resource

Categories

  • Cost of Disease
  • Economic Burden

Related Facts

  • Visual loss from subfoveal choroidal neovascularization, a characteristic of wet age-related macular degeneration (AMD), was found to have a profound impact on how patients felt about their health-related quality of…  
  • More than 1 million Americans ages 40-49 are estimated to have diabetic retinopathy. That grows to close to 2 million at ages 65-74.  
  • World Blindess from DR
     
  • Around 648,000 Americans age 80 and older are blind– 7% of the 80 and older population.  
  • Approximately 120,000 people have gone blind because of glaucoma– 9-12% of all cases of blindness in the U.S.